




***Podravka Group
business results
for 1 - 12 2025 period***

26th February 2026

Podravka 
GRUPA

Podravka Group revenues by segments



Podravka Group in 1 - 12 2025¹:

- **Own brands** → 0.9% higher sales,
- **Other sales** → (5.7%) lower sales,
- **Total Podravka Group** → (0.2%) lower sales revenues.

Food segment in 1 - 12 2025¹:

- **Own brands** → 1.3% higher sales due to the increase in sales of most business units,
- **Other sales** → 1.0% higher sales primarily due to the expansion of distribution on the US market,
- **Total Food** → 1.3% higher sales.

Pharmaceuticals segment in 1 - 12 2025¹:

- **Own brands** → 4.4% higher sales,
- **Other sales** → (1.4%) lower revenues, due to lower sales of trade goods in the Croatia market.
- **Total Pharma** → 3.3% higher sales revenues.

Agri segment in 2 - 12 2025²:

- **Own brands** → (2.3%) lower revenues,
- **Other sales** → (36.4%) lower revenues,
- **Other operating revenues³** → relates to income from incentives in agriculture and is lower by (0.5%).

¹Data refers to performance in 1-12 2025 compared to 1-12 2024 PF (pro-form result of the Podravka Group - simulating the Podravka Group's consolidated business result as if the acquired agricultural companies had been part of the Podravka Group in the previous year.)

²The comparative period for the Agri segment includes the 2-12 2024 period, given that the acquisition was finalised on 31 January 2025.

³Other operating revenues refer to agricultural subsidies, which the Podravka Group considers to be regular operating revenues within the newly acquired Agri segment.

Note: The Group's revenues are adjusted for the elimination of intersegmental transactions (consolidation adjustment) between the Food and Agri segments.


Revenues by business programs, categories and sub-segments

Realization of business programs, categories and sub-segments in 1 - 12 2025. ¹:

- **BU Culinary (-0.1%)** → lower sales than in the comparative period, due to increasing uncertainty in global markets, which led to heightened consumer caution, the decline in revenue was primarily recorded in the U.S. market, while the Croatian market achieved growth,
- **BU Soups (+3.6%)** → revenue growth of the business unit was realised in the key markets of Southeastern Europe, Croatia and Slovenia. The Clear soups and Creamy soups subcategories contribute most to a positive trend within the Soups business unit,
- **BU Cereals, Snack and Beverages (+9.4%)** → higher sales than in the comparative period. The markets of Croatia, Germany, Slovenia and Southeastern Europe contribute most, while the growth was recorded by all categories, led by the Cereals category, and the Tea and beverages category,
- **BU Creamy spreads and Desserts (+7.8%)** → revenue growth was recorded mainly in the market of Croatia, Germany and in the Southeastern Europe region, primarily due to the increase in the Creamy spreads category
- **BU Bakery (-6.1%)** → revenue decrease, primarily in the markets of Slovenia and Italy,
- **BU Fruit and Vegetables (+0.0%)** → recorded revenues at the same level as in the comparative period. The markets of Croatia, Bosnia and Herzegovina, and North Macedonia contribute most to the growth,
- **BU Basic food (+1.5%)** → higher sales, with the greatest contributions coming from the markets of the Czech Republic, Croatia and Bosnia and Herzegovina in the Rice and Pasta categories,
- **BU Meat products (+4.5%)** → higher sales, primarily on the markets of Croatia, the Czech Republic, Germany and Southeastern Europe. The revenue growth arises from the categories of Ready meals, and Pâtés,
- **BU Fish (-8.2%)** → lower sales, which is primarily caused by the lack of raw material, sardines, due to significantly lower catches in the Adriatic Sea, and thus lower sales in the Canned fish category,
- **Prescription drugs (+4.3%)** → higher sales, mainly due to the increase in sales of dermatological drugs category and cardiovascular drugs in the markets of Eastern and Southeastern Europe,
- **Non-prescription program (+5.0%)** → higher, as a result of the increase in sales of the OTC drugs subcategory in the markets of Eastern and Southeastern Europe,


- **Livestock subsegment (-3.0%)** → in relation to the comparable base in 2024, lower revenues, primarily due to lower market prices of fattened pigs and lower sales volumes as a result of restrictions caused by African swine fever,
- **Crop production subsegment (-9.0%)** → lower revenues, due to the fact that some smaller segments were not taken over in the acquisition, but their sales were recorded in the comparable period,
- **Industrial products subsegment (+1.9%)** → higher revenues due to higher sales of dairy products,
- **Energy and other subsegment (-0.5%)** → which includes biogas plants and smaller subsegments within the Agri segment, recorded lower revenues by -0.5%,
- **Other sales (-5.7%)** → in the Food segment, Other sales increased by EUR 0.5m (+1.0%), mainly as a result of the expansion of distribution activities in the US market and agreed cooperation with new principals, while in the Pharmaceuticals segment, Other sales dropped by EUR 0.4m (-1.4%), due to lower trade goods sales in the market of Croatia. In the Agri segment, Other sales is EUR 5.5m lower (-36.4%), due to lower sales of trade goods.

Sales and subsidies revenues by business units, categories and subsegments in 1 - 12 2025



¹Data refers to performance in 1-12 2025 compared to 1-12 2024 PF (pro-form result of the Podravka Group - simulating the Podravka Group's consolidated business result as if the acquired agricultural companies had been part of the Podravka Group in the previous year.) The comparative period for the Agri segment includes the 2-12 2024 period, given that the acquisition was finalised on 31 January 2025.

Operating revenues by region



(in EURm)	1-12 2024 PF	1-12 2025	Δ	% change
Markets of Croatia and Slovenia	601.2	600.2	(1.0)	(0.2%)
Southeastern Europe	174.7	180.3	5.6	3.2%
Western Europe and Overseas	111.2	106.1	(5.1)	(4.6%)
Central Europe	83.6	81.3	(2.2)	(2.7%)
Eastern Europe	45.6	50.8	5.1	11.3%
Other Operating revenues	27.3	27.2	(0.1)	(0.5%)
Consolidation adjustment ²	-	(4.9)	(4.9)	n/a
Podravka Group	1,043.7	1,041.1	(2.6)	(0.2%)

¹Data refers to performance in 1-12 2025 compared to 1-12 2024 PF (pro-form result of the Podravka Group - simulating the Podravka Group's consolidated business result as if the acquired agricultural companies had been part of the Podravka Group in the previous year.) The comparative period for the Agri segment includes the 2-12 2024 period, given that the acquisition was finalised on 31 January 2025.

²The Group's revenues are adjusted for the elimination of intersegmental transactions (consolidation adjustment) between the Food and Agri segments.

Region's performance in 1 - 12 2025¹:

- **Markets of Croatia and Slovenia (-0.2%)** → **The Food** segment increased revenues by EUR 13.5m (+4.5%), mainly driven by higher sales in Croatia across almost all Business units. **Pharmaceuticals** declined by EUR 5.6m (-7.9%) due to lower sales on the Croatian market. Compared to the 2024 comparable period, **Agri** revenues were lower by EUR 8.9m (-3.8%), reflecting lower sales in Crop production (as certain smaller segments were not acquired) and in Livestock, due to lower fattened pig prices and reduced volumes impacted by African swine fever,
- **Southeastern Europe (+3.2%)** → **Food** revenues grew by EUR 2.1m (+1.8%), with strongest contribution from Bosnia and Herzegovina, Montenegro, Kosovo and North Macedonia, particularly in Soups, Creamy spreads and desserts, Meat products, and Cereals, snack and beverages. Growth was achieved despite external pressures and regulatory changes in certain markets. **Pharmaceuticals** increased by EUR 3.9m (+7.7%), driven by Prescription drugs, while **Agri** revenues were EUR 0.4m (-3.8%) lower compared to the comparable base, due to lower sales in Serbia.
- **WE and Overseas region (-4.6%)** → **Food** revenues decreased by EUR 5.0m (-4.8%), mainly due to lower Bakery sales in Italy and slightly lower revenues from the Culinary Business Program in the U.S., amid increased global uncertainty and more cautious consumer behaviour. Germany recorded strong revenue growth following 2024 restructuring. **Pharmaceuticals** grew by EUR 1.1m (+43.8%), primarily due to Prescription drugs in the UK, while **Agri** revenues were EUR 1.2m (-23.9%) lower compared to the comparable base,
- **Central Europe (-2.7%)** → **Food** revenues declined by EUR 2.5m (-3.5%) due to lower Other sales in the Czech Republic, Poland, and Romania. **Pharmaceuticals** increased by EUR 0.7m (+6.1%) due to higher sales in Poland and Czech Republic, while **Agri** revenues were EUR 0.5m (-30.5%) lower compared to the comparable base,
- **Eastern Europe (+11.3%)** → the **Pharmaceuticals** segment achieved revenue growth of EUR 5.7m (+14.4%), primarily in the Prescription drugs category, while the **Food** segment achieved revenue decline of EUR 0.6m (-9.5%).

Profitability of the Food segment

Food segment (in EURm)	REPORTED				NORMALISED ¹			
	1-12 2024	1-12 2025	Δ	%	1-12 2024	1-12 2025	Δ	%
Sales revenue	591.6	599.2	7.6	1.3%	591.6	599.2	7.6	1.3%
Gross profit	202.0	204.5	2.5	1.2%	202.2	204.6	2.5	1.2%
EBITDA	69.5	76.7	7.2	10.3%	70.6	74.0	3.5	4.9%
EBIT	44.0	49.0	5.0	11.4%	45.1	46.3	1.2	2.6%
Net profit after MI	44.6	31.3	(13.2)	(29.7%)	35.8	28.3	(7.6)	(21.1%)
Gross margin	34.1%	34.1%		-2 bp	34.2%	34.1%		-2 bp
EBITDA margin	11.8%	12.8%		+105 bp	11.9%	12.4%		+43 bp
EBIT margin	7.4%	8.2%		+74 bp	7.6%	7.7%		+10 bp
Net profit margin after MI	7.5%	5.2%		-231 bp	6.1%	4.7%		-134 bp

Food segment profitability in 1 - 12 2025:

Gross profit

- is EUR 2.5m higher, with a gross margin approximately at the same level as in the comparative period,

EBITDA

- **Operating profit before depreciation and amortisation (EBITDA)** is EUR 7.2m (+10.3%) higher while **normalised operating profit before depreciation and amortisation (EBITDA)** is EUR 3.5m (+4.9%) higher primarily due to higher sales revenue, as well as process improvements and the optimisation of operating expenses, with EBITDA growth achieved despite investments in improving the material status of employees, which resulted in an increase in staff costs,

Net profit after MI

- **Normalised net profit after minority interests** is EUR 7.6m lower (-21.1%) due to higher depreciation costs given the completed significant investment cycle, as well as the costs of financing the acquisition of agricultural companies of the Fortenova Group. Podravka Inc. is the debtor of the borrowing for financing the acquisition, therefore the financing cost is formally borne by the Food segment.

¹Normalized for one-off impact.

Profitability of the Pharmaceuticals segment

Pharma segment (in EURm)	REPORTED				NORMALISED ¹			
	1-12 2024	1-12 2025	Δ	%	1-12 2024	1-12 2025	Δ	%
Sales revenue	174.9	180.7	5.8	3.3%	174.9	180.7	5.8	3.3%
Gross profit	89.6	95.2	5.6	6.2%	89.6	95.3	5.7	6.3%
EBITDA	45.9	48.9	3.1	6.7%	46.2	49.4	3.1	6.8%
EBIT	36.0	41.0	5.0	14.0%	36.8	39.7	2.9	8.0%
Net profit after MI	29.3	31.8	2.5	8.5%	28.4	30.7	2.4	8.3%
Gross margin	51.2%	52.6%		+143 bp	51.2%	52.7%		+149 bp
EBITDA margin	26.2%	27.1%		+84 bp	26.4%	27.3%		+88 bp
EBIT margin	20.6%	22.7%		+212 bp	21.0%	22.0%		+94 bp
Net profit margin after MI	16.8%	17.6%		+84 bp	16.2%	17.0%		+78 bp

Pharmaceuticals segment profitability in 1 - 12 2025:

Gross profit

- is EUR 5.6m (+6.2%) higher, with an increase in gross margin from 51.2% to 52.6%,

EBITDA

- **Operating profit before depreciation and amortisation (EBITDA)** is EUR 3.1m (+6.7%) higher, mainly caused by the increase in sales revenues and gross profit, despite investments in improving the material status of employees, which resulted in an increase in staff costs,

Net profit after MI

- **Net profit after minority interests** is EUR 2.5m higher (+8.5%), while **normalised net profit after minority interests** is EUR 2.4m (+8.3%) higher.

¹Normalized for one-off impact.

Profitability of the Agri segment

Agri segment (in EURm)	REPORTED				NORMALISED ¹			
	2-12 2024 PF ²	2-12 2025 ³	Δ	%	2-12 2024 PF ²	2-12 2025 ³	Δ	%
Operating revenues	277.2	266.1	(11.1)	(4.0%)	277.2	266.1	(11.1)	(4.0%)
Sales revenue	249.8	238.9	(10.9)	(4.4%)	249.8	238.9	(10.9)	(4.4%)
Other operating revenues ⁴	27.3	27.2	(0.1)	(0.5%)	27.3	27.2	(0.1)	(0.5%)
Gross profit	42.6	43.3	0.7	1.7%	42.6	45.3	2.7	6.4%
EBITDA	46.2	101.0	54.8	118.5%	45.3	44.5	(0.8)	(1.8%)
EBIT	7.0	79.7	72.7	n/a	24.1	23.2	(0.8)	(3.5%)
Net profit after MI	(4.6)	72.4	77.0	n/a	10.1	15.8	5.7	56.4%
Gross margin	15.4%	16.3%		+92 bp	15.4%	17.0%		+167 bp
EBITDA margin	16.7%	38.0%		+2128 bp	16.4%	16.7%		+37 bp
EBIT margin	2.5%	30.0%		+2743 bp	8.7%	8.7%		+4 bp
Net profit margin after MI	(1.6%)	27.2%		+2886 bp	3.6%	5.9%		+229 bp

Agri segment profitability in 2-12 2025:

Gross profit

- in relation to the comparable base in 2024, the Agri segment recorded **normalised gross profit** higher by EUR 2.7m (+6.4%), with the higher gross margin, which is at a level of 17.0%,

EBITDA

- Within the Agri segment, the difference between the paid compensation and the net acquired assets of the agricultural companies of the Fortenova Group was recorded in the amount of EUR 57.5m, which is shown in the **reported operating profit before depreciation and amortisation (EBITDA)**. Since this is treated as a one-off item, the **normalised operating profit before depreciation and amortisation (EBITDA)** is reduced by the stated effect and amounts to EUR 44.5m and is lower than the comparable base by EUR 0.8m (-1.8%),

Net profit after MI

- **Normalised net profit after minority interests** amounts to EUR 15.8m and is higher than the comparable base by EUR 5.7m.

¹Normalized for one-off impact.

²Pro forma result for the Agri segment in 2-12 2024, simulating the consolidated business result of the acquired agricultural companies during 2024, when these companies were not yet part of the Podravka Group. The comparative period includes the 2-12 2024 period, as the acquisition was completed on 31 January 2025.

³Given that the Podravka Group acquired control over the Agri segment on 31 January 2025, the results of the Agri segment include results for the 2-12 2025 period.

⁴Other operating revenues refer to agricultural subsidies, which the Podravka Group considers to be regular operating revenues within the newly acquired Agri segment.

Profitability of the Podravka Group

Podravka Group (in EURm)	REPORTED					NORMALISED ¹				
	1-12 2024 ²	1-12 2024 PF ³	1-12 2025	Δ	%	1-12 2024 ²	1-12 24 PF ³	1-12 2025	Δ	%
Operating revenues	766.5	1,043.7	1,041.1	(2.6)	(0.2%)	766.5	1,043.7	1,041.1	(2.6)	(0.2%)
Sales revenue	766.5	1,016.3	1,013.9	(2.5)	(0.2%)	766.5	1,016.3	1,013.9	(2.5)	(0.2%)
Other operating revenues	0.0	27.3	27.2	(0.1)	(0.5%)	0.0	27.3	27.2	(0.1)	(0.5%)
Gross profit	291.6	334.2	341.9	7.7	2.3%	291.8	334.4	344.1	9.8	2.9%
EBITDA	115.4	161.6	226.5	64.8	40.1%	116.8	162.1	167.7	5.6	3.5%
EBIT	80.0	87.0	169.6	82.6	94.9%	81.9	106.0	109.1	3.1	2.9%
Net profit after MI	73.9	69.3	135.4	66.1	95.3%	64.2	74.3	74.6	0.3	0.5%
Gross margin	38.0%	32.0%	32.8%		+82 bp	38.1%	32.0%	33.1%		+102 bp
EBITDA margin	15.1%	15.5%	21.8%		+627 bp	15.2%	15.5%	16.1%		+58 bp
EBIT margin	10.4%	8.3%	16.3%		+795 bp	10.7%	10.2%	10.5%		+32 bp
Net profit margin after MI	9.6%	6.6%	13.0%		+636 bp	8.4%	7.1%	7.2%		+5 bp

Profitability of the Podravka Group in 1 - 12 2025:

Gross profit

- recorded EUR 7.7m (+2.3%) higher gross profit, with a gross margin at approximately the same level as in the comparative period,

EBITDA

- is EUR 64.8m (+40.1%) higher, while **normalised operating profit before depreciation and amortisation** (EBITDA) is EUR 5.6m (+3.5%) higher. The difference between operating profit before depreciation and amortisation and normalised operating profit before depreciation and amortisation primarily refers to the recorded difference between the paid compensation and the net acquired assets of the agricultural companies of the Fortenova Group in the amount of EUR 57.5m, which is treated as a one-off item,

Net profit after MI

- the Group's **normalised net profit after minority interests** is EUR 0.3m (+0.5%) higher than the comparable base in 2024, whereby the Food segment (which formally bears the costs of financing the acquisition of agricultural companies within the Fortenova Group) recorded a decline in normalised net profit, while the Pharmaceutical and Agri segments reported growth in normalised net profit.

¹Normalized for one-off impact.

²Official result of the Podravka Group for 2024, comprising the Food and Pharmaceutical segments.

³Pro forma result of the Podravka Group for 2024, simulating the Podravka Group's consolidated business result as if the acquired agricultural companies had been part of the Podravka Group in the previous year. The comparative period for the Agri segment includes the 2-12 2024 period, given that the acquisition was finalised on 31 January 2025.

Note: consolidated result of the Podravka Group is presented after elimination of intragroup transactions.

Business expenses influenced by investments in improving the material status of employees

Business expenses 1 - 12 2025 vs. 1 - 12 2024 % change	REPORTED	NORMALIZED ¹
Cost of goods sold (COGS)	47.2% ↑	46.8% ↑
General and administrative expenses (G&A)	14.5% ↑	18.9% ↑
Sales and distribution costs (S&D)	11.4% ↑	11.8% ↑
Marketing expenses (MEX)	7.2% ↑	7.1% ↑
Other expenses / (revenues), net	(<100%) ↓	(136.8%) ↓
Total	26.9% ↑	36.1% ↑

Business expenses 1 - 12 2025 vs. 1 - 12 2024 PF % change	REPORTED	NORMALIZED ¹
Cost of goods sold (COGS)	(1.5%) ↓	(1.7%) ↓
General and administrative expenses (G&A)	(4.7%) ↓	(1.9%) ↓
Sales and distribution costs (S&D)	2.9% ↑	3.2% ↑
Marketing expenses (MEX)	4.9% ↑	4.8% ↑
Other expenses / (revenues). net	(<100%) ↓	(114.9%) ↓
Total	(8.9%) ↓	(2.5%) ↓

Key highlights of expenses in 1 - 12 2025²:

- Cost of goods sold (COGS):**

Cost of goods sold is EUR 10.3m (-1.5%) lower, whereby in the Food and Pharmaceuticals segments they are higher primarily due to the increase in material rights of employees, while in the Agri segment they are lower as a result of lower sales revenues despite the increase in material rights of employees.

- General and administrative expenses (G&A):**

General and administrative expenses are EUR 3.4m (-4.7%) lower, which results from the parts of operations where cost savings were achieved through process improvements and workflow optimisation despite the increase in material rights of employees.

- Sales and distribution costs (S&D):**

In the observed period, selling and distribution costs are EUR 3.1m (+2.9%) higher, which is affected by all three segments primarily due to the increase in material rights of employees compared to a comparable base.

- Marketing expenses (MEX):**

In the reporting period, marketing expenses are EUR 2.7m higher (+4.9%), which arises from the Food and Pharmaceuticals segments, primarily due to an increase in costs of the marketing department following the improved material rights of employees in relation to the comparative period.

- Other expenses (revenues), net:**


In the reporting period, other expenses and income, net amounted to EUR -65.8m (positive impact), which primarily refers to the recorded difference between the paid compensation and the net acquired assets of the agricultural companies of the Fortenova Group in the amount of EUR 57.5m, which is treated as a one-off item.

¹Normalized for one-off impact.

²Data refers to performance in 1-12 2025 compared to 1-12 2024 PF (pro-form result of the Podravka Group - simulating the Podravka Group's consolidated business result as if the acquired agricultural companies had been part of the Podravka Group in the previous year.) The comparative period for the Agri segment includes the 2-12 2024 period, given that the acquisition was finalised on 31 January 2025.

The increase in indebtedness stems from the acquisition of the newly acquired Agri segment

(in EURm) ¹	2024	1-12 2025	% change
Financial debt ²	57.7	421.7	n/a
Cash and cash equivalents	27.1	40.2	48.3%
Net debt	30.5	381.5	n/a
Interest expense	0.96	16.05	n/a
Net debt / normalized EBITDA	0.26	2.27	n/a
Normalized EBIT / Interest expense	85.3	6.8	(92.0%)
Equity to total assets ratio	74.7%	54.8%	n/a



Key highlights:

- The increase in **net debt** as at 31 December 2025 compared to 31 December 2024 is a result of financing the acquisition of agricultural companies of the Fortenova Group. The transaction value is EUR 333m, for which Podravka Inc. secured EUR 283m through a club loan from Croatian banks, while the EBRD participated with EUR 50m. An additional increase relates to the right-of-use assets related to the newly acquired Agri segment.
- **Net debt/Normalised EBITDA** is 2.27, and the indicator is obtained in a way that income statement items are calculated at the level of the last 12 months, while balance sheet items are taken at the end of the period, whereby for the newly acquired Agri segment the current calculation includes income statement items for the period 2-12 2025, given that the Podravka Group acquired control over the segment on 31 January 2025 and therefore the indicator is currently at a slightly higher level.
- **Weighted average cost of debt excluding liabilities for right-of-use assets:**
 - As at 31 December 2025 → 2.9%,
 - As at 31 December 2024 → 0.8%.

¹All indicators were calculated in such a way that the income statement items were calculated at the level of the last 12 months, while the balance sheet items were taken at the end of the period, whereby for the newly acquired Agri segment, the current calculation includes income statement items for the period 2-6, 2025, given that the Podravka Group acquired control over the segment on 31st January 2025

²Long-term and short-term loans + lease liabilities + financial liabilities at fair value through profit or loss.


Key highlights of the cash flow

Working capital movement in BS	31 December 2025 / 31 December 2024		Impact
Inventories	↑	4.7%	<ul style="list-style-type: none"> inventories of the Podravka Group are EUR 11.2m higher than as at 31 December 2024, where the inventories of the Food and Pharmaceuticals segments are slightly higher due to increased volume of operations and are maintained at the optimum level, while the Agri segment's inventories are slightly lower,
Trade and other receivables	↓	(1.9%)	<ul style="list-style-type: none"> trade and other receivables of the Podravka Group are EUR 4.0m lower than as at 31 December 2024, where this arises from the Food segment in the part of lower other receivables, while the Pharmaceuticals segment records an increase in trade receivables.
Trade and other payables	↑	2.1%	<ul style="list-style-type: none"> trade and other payables of the Podravka Group are EUR 3.0m higher compared to the comparable base, due to higher payables in the Agri segment, partly reduced by lower trade payables in the Food and Pharmaceuticals segments.

(in EURm)	1-12 2024	1-12 2025	Δ
Net cash from operating activities	88.8	99.3	11.8%
Net cash from investing activities	(68.2)	(362.8)	(432.4%)
Net cash from financing activities	(36.1)	276.7	867.3%
Net change of cash and cash equivalents	(15.4)	13.1	185.1%


- **Capital expenditures** totalled EUR 82.0m in 2025.

Net cash flow from operating activities as % of sales



Podravka's share price movement

PODR share price movement in 1 – 12 2025



Market activity with PODR share

(EUR; units)	1-12 2024	1-12 2025	% change
Average daily price	157.7	147.8	(6.3%)
Average daily number of transactions	12	13	15.4%
Average daily volume	725	629	(13.2%)
Average daily turnover	114,325	92,218	(19.3%)
Reported earnings per share	10.5 ¹	19.2	83.0%
Normalized earnings per share	9.1 ¹	10.6	16.1%

Last price on
31.12.2024

148.50
EUR

Dividend paid per
share

3.20 EUR

Last price on
31.12.2025

150.0
EUR

Dividend yield²

2.2%

¹Based on the results for 2024 ²Dividend yield calculated based on the last mkt. price at the end of 2024.

Contact

Podravka Inc.

Ante Starčevića 32, 48 000 Koprivnica

www.podravka.hr

Investor Relations

ir@podravka.hr



***Podravka Group
business results
for 1 - 12 2025 period***

26th February 2026

Podravka 
GRUPA